Katarzyna Radke

Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma

D. Gisselsson, K. Wennerberg, K. Pietras, 2020, Science Translational Medicine.

Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance

J. Karlsson, D. Gisselsson, Kristina Aaltonen, 2022, bioRxiv.

Patient-derived models: Advanced tools for precision medicine in neuroblastoma

Kristina Aaltonen, D. Bexell, A. Adamska, 2023, Frontiers in Oncology.

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma

K. Hansson, J. Pastor, C. Welinder, 2019, EMBO molecular medicine.

Anti-tumor effects of rigosertib in high-risk neuroblastoma

J. Karlsson, D. Gisselsson, K. Pietras, 2021, Translational oncology.